BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, Aguilar D, Krum H, McMurray JJ. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008;29:1224-40. [PMID: 18424786 DOI: 10.1093/eurheartj/ehn156] [Cited by in Crossref: 143] [Cited by in F6Publishing: 124] [Article Influence: 10.2] [Reference Citation Analysis]
Number Citing Articles
1 Nakamura H, Matoba S, Iwai-kanai E, Kimata M, Hoshino A, Nakaoka M, Katamura M, Okawa Y, Ariyoshi M, Mita Y, Ikeda K, Okigaki M, Adachi S, Tanaka H, Takamatsu T, Matsubara H. p53 Promotes Cardiac Dysfunction in Diabetic Mellitus Caused by Excessive Mitochondrial Respiration-Mediated Reactive Oxygen Species Generation and Lipid Accumulation. Circ: Heart Failure 2012;5:106-15. [DOI: 10.1161/circheartfailure.111.961565] [Cited by in Crossref: 57] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
2 Eickhoff MK, Olsen FJ, Frimodt-Møller M, Diaz LJ, Faber J, Jensen MT, Rossing P, Persson F. Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial. J Diabetes Complications 2020;34:107590. [PMID: 32340841 DOI: 10.1016/j.jdiacomp.2020.107590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rahman I, Wolk A, Larsson SC. The relationship between sweetened beverage consumption and risk of heart failure in men. Heart 2015;101:1961-5. [DOI: 10.1136/heartjnl-2015-307542] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
4 Sattar N, Petrie MC, Zinman B, Januzzi JL. Novel Diabetes Drugs and the Cardiovascular Specialist. J Am Coll Cardiol. 2017;69:2646-2656. [PMID: 28545639 DOI: 10.1016/j.jacc.2017.04.014] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 11.2] [Reference Citation Analysis]
5 Carrasco-sánchez FJ, Gomez-huelgas R, Formiga F, Conde-martel A, Trullàs JC, Bettencourt P, Arévalo-lorido JC, Pérez-barquero MM. Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: Findings from the RICA registry. Diabetes Research and Clinical Practice 2014;104:410-9. [DOI: 10.1016/j.diabres.2014.03.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
6 Li C, Li J, Cai X, Sun H, Jiao J, Bai T, Zhou XW, Chen X, Gill DL, Tang XD. Protein kinase D3 is a pivotal activator of pathological cardiac hypertrophy by selectively increasing the expression of hypertrophic transcription factors. J Biol Chem 2011;286:40782-91. [PMID: 21971046 DOI: 10.1074/jbc.M111.263046] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
7 Vicha M, Skala T, Jelinek L, Pavlu L, Jarkovsky J, Dusek L, Benesova K, Taborsky M. Pharmacotherapy of diabetes mellitus in patients with heart failure - a nation-wide analysis of contemporary treatment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021. [PMID: 34897297 DOI: 10.5507/bp.2021.069] [Reference Citation Analysis]
8 Salem ESB, Fan GC. Pathological Effects of Exosomes in Mediating Diabetic Cardiomyopathy. Adv Exp Med Biol 2017;998:113-38. [PMID: 28936736 DOI: 10.1007/978-981-10-4397-0_8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
9 Cheng SY, Yang LM, Sun ZS, Zhang XX, Zhu XY, Meng LF, Guo SZ, Zhuang XH, Luo P, Cui WP. Risk factors for mortality within 6 mo in patients with diabetes undergoing urgent-start peritoneal dialysis: A multicenter retrospective cohort study. World J Diabetes 2022; 13(4): 376-386 [DOI: 10.4239/wjd.v13.i4.376] [Reference Citation Analysis]
10 Aljohar A, Alhabib KF, Kashour T, Hersi A, Al Habeeb W, Ullah A, Elasfar A, Almasood A, Ghabashi A, Mimish L, Alghamdi S, Abuosa A, Malik A, Hussein GA, Al-Murayeh M, AlFaleh H. The prognostic impact of hyperglycemia on clinical outcomes of acute heart failure: Insights from the heart function assessment registry trial in Saudi Arabia. J Saudi Heart Assoc 2018;30:319-27. [PMID: 30072842 DOI: 10.1016/j.jsha.2018.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Shah AM, Hung CL, Shin SH, Skali H, Verma A, Ghali JK, Køber L, Velazquez EJ, Rouleau JL, McMurray JJ, Pfeffer MA, Solomon SD. Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. Am Heart J 2011;162:685-91. [PMID: 21982661 DOI: 10.1016/j.ahj.2011.07.015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
12 Krum H, Abraham WT. Heart failure. The Lancet 2009;373:941-55. [DOI: 10.1016/s0140-6736(09)60236-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
13 Straw S, Witte KK, Kearney MT. Heart failure: A preventable and treatable complication of type 2 diabetes. J Diabetes 2019;11:613-6. [PMID: 31037815 DOI: 10.1111/1753-0407.12930] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 van Kuijk JP, Flu WJ, Valentijn TM, Chonchol M, Kuiper RJ, Verhagen HJ, Bax JJ, Poldermans D. Influence of left ventricular dysfunction (diastolic versus systolic) on long-term prognosis in patients with versus without diabetes mellitus having elective peripheral arterial surgery. Am J Cardiol 2010;106:860-4. [PMID: 20816129 DOI: 10.1016/j.amjcard.2010.05.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Patel SK, Wai B, Ord M, MacIsaac RJ, Grant S, Velkoska E, Panagiotopoulos S, Jerums G, Srivastava PM, Burrell LM. Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes. Am J Hypertens 2012;25:216-22. [PMID: 21993363 DOI: 10.1038/ajh.2011.188] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
16 Laohabut I, Songsangjinda T, Kaolawanich Y, Yindeengam A, Krittayaphong R. Myocardial Extracellular Volume Fraction and T1 Mapping by Cardiac Magnetic Resonance Compared Between Patients With and Without Type 2 Diabetes, and the Effect of ECV and T2D on Cardiovascular Outcomes. Front Cardiovasc Med 2021;8:771363. [PMID: 34950715 DOI: 10.3389/fcvm.2021.771363] [Reference Citation Analysis]
17 Ji L, Pranoto A, Andag-Silva A, Deerochanawong C, Van Phuoc D, Tan KCB, Tan K, Sung-Rae K, Mohamed MB, Shah P, Dang TH. Retracted: Western pacific consensus proposals for management of prediabetes. Int J Clin Pract 2021;:e14019. [PMID: 33480067 DOI: 10.1111/ijcp.14019] [Reference Citation Analysis]
18 Wong AK, Alzadjali MA, Choy AJ, Lang CC. Insulin Resistance: A Potential New Target for Therapy in Patients with Heart Failure. Cardiovascular Therapeutics 2008;26:203-13. [DOI: 10.1111/j.1755-5922.2008.00053.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
19 Lai S, Fu X, Yang S, Zhang S, Lin Q, Zhang M, Chen H. G protein-coupled receptor kinase-2: A potential biomarker for early diabetic cardiomyopathy. J Diabetes 2020;12:247-58. [PMID: 31680450 DOI: 10.1111/1753-0407.12991] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
20 Deaton C, Mamas MA, Rutter MK, Gibson M, Bowell S, Byrne R, Coezy K, Gow J, Williams S. Glucose and Insulin Abnormalities in Patients with Heart Failure. European Journal of Cardiovascular Nursing 2011;10:75-87. [DOI: 10.1016/j.ejcnurse.2010.08.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
21 Mcmurray JJV, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. The Lancet Diabetes & Endocrinology 2014;2:843-51. [DOI: 10.1016/s2213-8587(14)70031-2] [Cited by in Crossref: 219] [Cited by in F6Publishing: 101] [Article Influence: 27.4] [Reference Citation Analysis]
22 Ekeruo IA, Solhpour A, Taegtmeyer H. Metformin in Diabetic Patients with Heart Failure: Safe and Effective? Curr Cardiovasc Risk Rep 2013;7:417-22. [PMID: 24466358 DOI: 10.1007/s12170-013-0355-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
23 Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G, Gale CP, Batin PD, Ajjan R, Kearney L, Wheatcroft SB, Sapsford RJ, Witte KK, Kearney MT. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diabetes and Vascular Disease Research 2013;10:330-6. [DOI: 10.1177/1479164112471064] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 11.8] [Reference Citation Analysis]
24 Iyngkaran P, Majoni W, Cass A, Sanders P, Ronco C, Brady S, Kangaharan N, Ilton M, Hare DL, Thomas MC. Northern Territory perspectives on heart failure with comorbidities – understanding trial validity and exploring collaborative opportunities to broaden the evidence base. Heart Lung Circ 2015;24:536-43. [PMID: 25637942 DOI: 10.1016/j.hlc.2014.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
25 Heyne E, Schrepper A, Doenst T, Schenkl C, Kreuzer K, Schwarzer M. High‐fat diet affects skeletal muscle mitochondria comparable to pressure overload‐induced heart failure. J Cell Mol Med 2020;24:6741-9. [DOI: 10.1111/jcmm.15325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Romero SP, Andrey JL, Garcia-Egido A, Escobar MA, Perez V, Corzo R, Garcia-Domiguez GJ, Gomez F. Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community. Int J Cardiol 2013;166:404-12. [PMID: 22112681 DOI: 10.1016/j.ijcard.2011.10.141] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
27 Girerd N, Zannad F, Rossignol P. Review of heart failure treatment in type 2 diabetes patients: It's at least as effective as in non-diabetic patients! Diabetes & Metabolism 2015;41:446-55. [DOI: 10.1016/j.diabet.2015.06.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
28 Komajda M, Tavazzi L, Francq BG, Böhm M, Borer JS, Ford I, Swedberg K; SHIFT Investigators. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail 2015;17:1294-301. [PMID: 26377342 DOI: 10.1002/ejhf.347] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
29 Wang L, Cai Y, Jian L, Cheung CW, Zhang L, Xia Z. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy. Cardiovasc Diabetol 2021;20:2. [PMID: 33397369 DOI: 10.1186/s12933-020-01188-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
30 Masi S, Lautamäki R, Guiducci L, Di Cecco P, Porciello C, Pardini S, Morales MA, Chubuchny V, Salvadori PA, Emdin M, Sironi AM, Knuuti J, Neglia D, Nuutila P, Ferrannini E, Iozzo P. Similar patterns of myocardial metabolism and perfusion in patients with type 2 diabetes and heart disease of ischaemic and non-ischaemic origin. Diabetologia 2012;55:2494-500. [DOI: 10.1007/s00125-012-2631-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013;5:6. [PMID: 23415113 DOI: 10.1186/1758-5996-5-6] [Cited by in Crossref: 291] [Cited by in F6Publishing: 269] [Article Influence: 32.3] [Reference Citation Analysis]
32 Singh JS, Fathi A, Vickneson K, Mordi I, Mohan M, Houston JG, Pearson ER, Struthers AD, Lang CC. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol 2016;15:97. [PMID: 27422625 DOI: 10.1186/s12933-016-0419-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
33 Krum H, Skiba M, Wu S, Hopper I. Heart failure and dipeptidyl peptidase-4 inhibitors: Editorial. Eur J Heart Fail 2014;16:603-7. [DOI: 10.1002/ejhf.90] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
34 Anzalone R, Lo Iacono M, Loria T, Di Stefano A, Giannuzzi P, Farina F, La Rocca G. Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev. 2011;7:342-363. [PMID: 20972649 DOI: 10.1007/s12015-010-9196-4] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 8.3] [Reference Citation Analysis]
35 Krum H, Mcmurray JJ, Abraham WT, Dickstein K, Køber L, Desai AS, Solomon SD, Chiang Y, Gimpelewicz C, Reimund B, Ali MA, Tarnesby G, Massie BM; on behalf of the ATMOSPHERE Committees and Investigators. The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics: ATMOSPHERE: revised statistical analysis plan and baseline characteristics. Eur J Heart Fail 2015;17:1075-83. [DOI: 10.1002/ejhf.408] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
36 Dunbar SB, Reilly CM, Gary R, Higgins MK, Culler S, Butts B, Butler J. Randomized clinical trial of an integrated self-care intervention for persons with heart failure and diabetes: quality of life and physical functioning outcomes. J Card Fail 2015;21:719-29. [PMID: 26028261 DOI: 10.1016/j.cardfail.2015.05.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
37 Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, Jessup M, Kosiborod M, Pritchett AM, Ramasubbu K, Rosendorff C, Yancy C. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016;134. [DOI: 10.1161/cir.0000000000000450] [Cited by in Crossref: 107] [Cited by in F6Publishing: 62] [Article Influence: 17.8] [Reference Citation Analysis]
38 Standl E, Erbach M, Hanefeld M, Schnell O, Stratmann B, Tschoepe D. Clinical features and treatment of coronary heart disease in diabetes. In: Defronzo RA, Ferrannini E, Zimmet P, Alberti KGMM, editors. International Textbook of Diabetes Mellitus. Chichester: John Wiley & Sons, Ltd; 2015. pp. 1064-78. [DOI: 10.1002/9781118387658.ch73] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Helfand BK, Maselli NJ, Lessard DM, Yarzebski J, Gore JM, McManus DD, Saczynski JS, Goldberg RJ. Elevated serum glucose levels and survival after acute heart failure: a population-based perspective. Diab Vasc Dis Res 2015;12:119-25. [PMID: 25525077 DOI: 10.1177/1479164114559024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kwak S, Hwang IC, Park JJ, Park JH, Park JB, Cho GY. Sex-specific impact of diabetes mellitus on left ventricular systolic function and prognosis in heart failure. Sci Rep 2021;11:11664. [PMID: 34083601 DOI: 10.1038/s41598-021-91170-x] [Reference Citation Analysis]
41 Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933-989. [PMID: 18826876 DOI: 10.1016/j.ejheart.2008.08.005] [Cited by in Crossref: 1294] [Cited by in F6Publishing: 1135] [Article Influence: 92.4] [Reference Citation Analysis]
42 Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009;54:422-8. [PMID: 19628117 DOI: 10.1016/j.jacc.2009.04.049] [Cited by in Crossref: 128] [Cited by in F6Publishing: 107] [Article Influence: 9.8] [Reference Citation Analysis]
43 Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Diab Vasc Dis Res. 2014;11:133-173. [PMID: 24800783 DOI: 10.1177/1479164114525548] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 17.0] [Reference Citation Analysis]
44 Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010;16:200-6. [PMID: 20206893 DOI: 10.1016/j.cardfail.2009.10.022] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
45 Rushton CA, Satchithananda DK, Jones PW, Kadam UT. Non-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: A systematic review and meta-analysis. Int J Cardiol 2015;196:98-106. [PMID: 26080284 DOI: 10.1016/j.ijcard.2015.05.180] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
46 Hage FG, Iskandrian AE. Cardiovascular imaging in diabetes mellitus. J Nucl Cardiol. 2011;18:959-965. [PMID: 21785921 DOI: 10.1007/s12350-011-9431-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
47 Seong JM, Kim JJ, Kim HJ, Sohn HS. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. Cardiovasc Diabetol 2020;19:95. [PMID: 32571319 DOI: 10.1186/s12933-020-01060-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
48 Wood N, Straw S, Scalabrin M, Roberts LD, Witte KK, Bowen TS. Skeletal muscle atrophy in heart failure with diabetes: from molecular mechanisms to clinical evidence. ESC Heart Fail 2021;8:3-15. [PMID: 33225593 DOI: 10.1002/ehf2.13121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Lapik IA, Galchenko AV, Gapparova KM. Micronutrient status in obese patients: A narrative review. Obesity Medicine 2020;18:100224. [DOI: 10.1016/j.obmed.2020.100224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
50 Shah AM, Shin SH, Takeuchi M, Skali H, Desai AS, Køber L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, Keefe D, McMurray JJ, Pfeffer MA, Solomon SD. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail 2012;14:185-92. [PMID: 21965526 DOI: 10.1093/eurjhf/hfr125] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
51 Heck PM, Dutka DP. Insulin resistance and heart failure. Curr Heart Fail Rep 2009;6:89-94. [DOI: 10.1007/s11897-009-0014-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
52 Wang H, Zhang J, Shi CF, Jia J, Zhang ZM, Sun JJ, Lu BB. Distribution of traditional Chinese medicine syndromes in type 2 diabetes mellitus with chronic heart failure: A clinical study. Medicine (Baltimore) 2020;99:e21091. [PMID: 32791683 DOI: 10.1097/MD.0000000000021091] [Reference Citation Analysis]
53 Mohan M, Dihoum A, Mordi IR, Choy AM, Rena G, Lang CC. Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention. Front Cardiovasc Med 2021;8:746382. [PMID: 34660744 DOI: 10.3389/fcvm.2021.746382] [Reference Citation Analysis]
54 Triposkiadis F, Starling RC, Boudoulas H, Giamouzis G, Butler J. The cardiorenal syndrome in heart failure: cardiac?Heart Fail Rev. 2012;17:355-366. [PMID: 22086438 DOI: 10.1007/s10741-011-9291-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
55 Sato A, Yoshihisa A, Kanno Y, Takiguchi M, Miura S, Shimizu T, Nakamura Y, Yamauchi H, Owada T, Sato T, Suzuki S, Oikawa M, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Saitoh SI, Takeishi Y. Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus. ESC Heart Fail 2016;3:77-85. [PMID: 27774270 DOI: 10.1002/ehf2.12079] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
56 Yen DC, Watson MH, Burgess LD, Kuchibhatla M, Patel CB, Campbell KB, Vora AK. Positive Impact of Continuous-Flow Left Ventricular Assist Device Implantation on Glycemic Control in Patients with Type 2 Diabetes Mellitus and Advanced Chronic Systolic Heart Failure. Pharmacotherapy 2016;36:1210-6. [PMID: 27779786 DOI: 10.1002/phar.1853] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
57 Mordi NA, Mordi IR, Singh JS, Baig F, Choy AM, McCrimmon RJ, Struthers AD, Lang CC. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open 2017;7:e018097. [PMID: 29042392 DOI: 10.1136/bmjopen-2017-018097] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
58 Konduracka E, Cieslik G, Galicka-Latala D, Rostoff P, Pietrucha A, Latacz P, Gajos G, Malecki MT, Nessler J. Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. Acta Diabetol 2013;50:597-606. [PMID: 23358920 DOI: 10.1007/s00592-013-0455-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
59 Triposkiadis F, Giamouzis G, Butler J. The importance of managing diabetes correctly to prevent heart failure. Expert Review of Cardiovascular Therapy 2014;9:257-9. [DOI: 10.1586/erc.11.6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
60 Wilkinson MJ, Zadourian A, Taub PR. Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. Am J Cardiol 2019;124 Suppl 1:S3-S11. [PMID: 31741438 DOI: 10.1016/j.amjcard.2019.10.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
61 Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:853-72. [PMID: 29520964 DOI: 10.1002/ejhf.1170] [Cited by in Crossref: 234] [Cited by in F6Publishing: 181] [Article Influence: 58.5] [Reference Citation Analysis]
62 Chang P, Zhang X, Chen W, Zhang J, Wang J, Wang X, Yu J, Zhu X. Vasonatrin peptide, a synthetic natriuretic peptide, attenuates myocardial injury and oxidative stress in isoprenaline-induced cardiomyocyte hypertrophy. Peptides 2021;137:170474. [PMID: 33359394 DOI: 10.1016/j.peptides.2020.170474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Guo C, Shen L, Li H, Teng Y, Zhao S. Relation of Hemoglobin A1c to myocardial acoustic densitometry and left ventricular diastolic function in patients with Type 2 diabetes mellitus and without evident heart disease. Diabetes Research and Clinical Practice 2009;83:365-70. [DOI: 10.1016/j.diabres.2009.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
64 Elder DH, Singh JS, Levin D, Donnelly LA, Choy AM, George J, Struthers AD, Doney AS, Lang CC. Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study. Eur J Heart Fail 2016;18:94-102. [PMID: 26663216 DOI: 10.1002/ejhf.455] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
65 Macdonald MR, Petrie MC, Fisher M, Mcmurray JJV. Pharmacologic management of patients with both heart failure and diabetes. Curr Heart Fail Rep 2009;6:126-32. [DOI: 10.1007/s11897-009-0019-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Mcmurray JJ, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, Lewsey JD, Krum H. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure. JACC: Heart Failure 2018;6:8-17. [DOI: 10.1016/j.jchf.2017.08.004] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 18.0] [Reference Citation Analysis]
67 Sone H. Diabetes Mellitus. Encyclopedia of Cardiovascular Research and Medicine. Elsevier; 2018. pp. 9-16. [DOI: 10.1016/b978-0-12-809657-4.99593-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Stevens AL, Hansen D, Vandoren V, Westerlaken R, Creemers A, Eijnde BO, Dendale P. Mandatory oral glucose tolerance tests identify more diabetics in stable patients with chronic heart failure: a prospective observational study. Diabetol Metab Syndr 2014;6:44. [PMID: 24673860 DOI: 10.1186/1758-5996-6-44] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
69 Garcia-Egido A, Andrey JL, Puerto JL, Aranda RM, Pedrosa MJ, López-Sáez JB, Rosety M, Gomez F. Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. Int J Clin Pract 2015;69:550-9. [PMID: 25707623 DOI: 10.1111/ijcp.12567] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
70 Mishra PK, Ying W, Nandi SS, Bandyopadhyay GK, Patel KK, Mahata SK. Diabetic Cardiomyopathy: An Immunometabolic Perspective. Front Endocrinol (Lausanne) 2017;8:72. [PMID: 28439258 DOI: 10.3389/fendo.2017.00072] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
71 García-González P, Fabregat-Andrés Ó, Cozar-Santiago P, Sánchez-Jurado R, Estornell-Erill J, Valle-Muñoz A, Quesada-Dorador A, Payá-Serrano R, Ferrer-Rebolleda J, Ridocci-Soriano F. Cardiac sympathetic innervation assessed with (123)I-MIBG retains prognostic utility in diabetic patients with severe left ventricular dysfunction evaluated for primary prevention implantable cardioverter-defibrillator. Rev Esp Med Nucl Imagen Mol 2016;35:74-80. [PMID: 26514320 DOI: 10.1016/j.remn.2015.08.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Sandhu P, Ong JP, Garg V, Altaha M, Bello O, Singal SR, Verma S, Yan AT, Connelly KA. The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF). Acta Diabetol 2021;58:633-41. [PMID: 33483855 DOI: 10.1007/s00592-020-01661-y] [Reference Citation Analysis]
73 Chung YH, Lu KY, Chiu SC, Lo CJ, Hung LM, Huang JP, Cheng ML, Wang CH, Tsai CK, Lin YC, Chang SH, Lin G. Early Imaging Biomarker of Myocardial Glucose Adaptations in High-Fat-Diet-Induced Insulin Resistance Model by Using 18F-FDG PET and [U-13C]glucose Nuclear Magnetic Resonance Tracer. Contrast Media Mol Imaging 2018;2018:8751267. [PMID: 30116165 DOI: 10.1155/2018/8751267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Schmidt S, Hendricks V, Griebenow R, Riedel R. Demographic change and its impact on the health-care budget for heart failure inpatients in Germany during 1995-2025. Herz 2013;38:862-7. [PMID: 24065050 DOI: 10.1007/s00059-013-3955-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
75 Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes H, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Sousa Uva M, Taskinen M, Tendera M, Tuomilehto J, Valensi P, Luis Zamorano J, Luis Zamorano J, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Anton Sirnes P, Luis Tamargo J, Tendera M, Torbicki A, Wijns W, Windecker S, De Backer G, Anton Sirnes P, Alegria Ezquerra E, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Ž, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Luis Tamargo J, Viigimaa M, Vlachopoulos C, Xuereb RG; Grupo de Trabajo de la Sociedad Europea de Cardiología sobre diagnóstico y tratamiento de la cardiopatía isquémica estable, Grupo de Trabajo de la Sociedad Europea de Cardiología sobre diagnóstico y tratamiento de la cardiopatía isquémica estable, Grupo de Trabajo de la Sociedad Europea de Cardiología sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Revista Española de Cardiología 2014;67:136.e1-136.e56. [DOI: 10.1016/j.recesp.2013.10.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
76 Wallner M, Eaton DM, von Lewinski D, Sourij H. Revisiting the Diabetes-Heart Failure Connection. Curr Diab Rep 2018;18:134. [PMID: 30343339 DOI: 10.1007/s11892-018-1116-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
77 António N, Elvas L, Gonçalves L, Providência LA. Cardiac resynchronization therapy in the elderly: a realistic option for an increasing population? Int J Cardiol 2012;155:49-51. [PMID: 21334076 DOI: 10.1016/j.ijcard.2011.01.079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
78 Seferovic JP, Solomon SD, Seely EW. Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. Ther Adv Endocrinol Metab 2020;11:2042018820970444. [PMID: 33489085 DOI: 10.1177/2042018820970444] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
79 Wai B, Kearney LG, Hare DL, Ord M, Burrell LM, Srivastava PM. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012;11:14. [PMID: 22330091 DOI: 10.1186/1475-2840-11-14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
80 Dhillon S. Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. Drugs 2013;73:1451-62. [PMID: 23881669 DOI: 10.1007/s40265-013-0098-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
81 Li L, Li G, Chen H, Feng Z, Zhang L, Chen L, Fan L. Role of Diabetes Mellitus in Acute Coronary Syndrome Patients with Heart Failure and Midrange Ejection Fraction Who Have Undergone Percutaneous Coronary Intervention: A 3-Year Case-Series Follow-Up Retrospective Study. Diabetes Metab Syndr Obes 2021;14:4931-44. [PMID: 35002266 DOI: 10.2147/DMSO.S339209] [Reference Citation Analysis]
82 Chen P, Li S, Lei X, Liu Z, Wu D, Luo Y, Xu D. Free triiodothyronine levels and short-term prognosis in chronic heart failure patients with type 2 diabetes. Am J Med Sci 2015;350:87-94. [PMID: 26164865 DOI: 10.1097/MAJ.0000000000000524] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
83 Currie G, Delles C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis. 2013;7:13-24. [PMID: 24379690 DOI: 10.2147/ijnrd.s40522] [Cited by in Crossref: 5] [Cited by in F6Publishing: 33] [Article Influence: 0.6] [Reference Citation Analysis]
84 Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol 2011;22:460-6. [PMID: 21897230 DOI: 10.1097/MOL.0b013e32834b4994] [Cited by in Crossref: 71] [Cited by in F6Publishing: 28] [Article Influence: 7.1] [Reference Citation Analysis]
85 Nasir S, Aguilar D. Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement. Am J Cardiol 2012;110:50B-7B. [PMID: 23062568 DOI: 10.1016/j.amjcard.2012.08.031] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
86 Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-2442. [PMID: 18799522 DOI: 10.1093/eurheartj/ehn309] [Cited by in Crossref: 1959] [Cited by in F6Publishing: 1630] [Article Influence: 139.9] [Reference Citation Analysis]
87 Paulus WJ, Dal Canto E. Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. JACC Heart Fail 2018;6:1-7. [PMID: 29284577 DOI: 10.1016/j.jchf.2017.07.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
88 Packer M. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure. Circulation. 2017;136:1548-1559. [PMID: 29038209 DOI: 10.1161/circulationaha.117.030418] [Cited by in Crossref: 101] [Cited by in F6Publishing: 39] [Article Influence: 20.2] [Reference Citation Analysis]
89 Stevens AL, Hansen D, Herbots L, Wens I, Creemers A, Dendale P, Eijnde BO. Exercise training improves insulin release during glucose tolerance testing in stable chronic heart failure patients. J Cardiopulm Rehabil Prev 2015;35:37-46. [PMID: 25533903 DOI: 10.1097/HCR.0000000000000092] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
90 Zhou Y, Wang M, Wang S, Li N, Zhang S, Tang S, Shi Q, Zhao Y, Li J, Zeng Y, Song H, Tian H, Li S, Li S. Diabetes in Patients With Heart Failure With Reduced Ejection Fraction During Hospitalization: A Retrospective Observational Study. Front Endocrinol (Lausanne) 2021;12:727188. [PMID: 34456878 DOI: 10.3389/fendo.2021.727188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
91 Yoshihisa A, Watanabe S, Kanno Y, Takiguchi M, Sato A, Yokokawa T, Miura S, Shimizu T, Abe S, Sato T, Suzuki S, Oikawa M, Sakamoto N, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Saitoh SI, Takeishi Y. The CHA2DS2-VASc score as a predictor of high mortality in hospitalized heart failure patients. ESC Heart Fail 2016;3:261-9. [PMID: 27867527 DOI: 10.1002/ehf2.12098] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
92 Moradi G, Shokri A, Mohamadi-Bolbanabad A, Zareie B, Piroozi B. Evaluating the quality of care for patients with type 2 diabetes mellitus based on the HbA1c: A national survey in Iran. Heliyon 2021;7:e06485. [PMID: 33768178 DOI: 10.1016/j.heliyon.2021.e06485] [Reference Citation Analysis]
93 Lazareva NV, Oshchepkova EV, Orlovsky AA, Tereschenko SN. [Clinical characteristics and quality assessment of the treatment of patients with chronic heart failure with diabetes mellitus]. Ter Arkh 2020;92:37-44. [PMID: 32598696 DOI: 10.26442/00403660.2020.04.000474] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Aguilar D. Management of type 2 diabetes in patients with heart failure. Curr Treat Options Cardiovasc Med 2008;10:465-75. [PMID: 19026177 DOI: 10.1007/s11936-008-0039-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
95 Ménard SL, Croteau E, Sarrhini O, Gélinas R, Brassard P, Ouellet R, Bentourkia M, van Lier JE, Des Rosiers C, Lecomte R, Carpentier AC. Abnormal in vivo myocardial energy substrate uptake in diet-induced type 2 diabetic cardiomyopathy in rats. Am J Physiol Endocrinol Metab 2010;298:E1049-57. [PMID: 20159856 DOI: 10.1152/ajpendo.00560.2009] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 6.0] [Reference Citation Analysis]
96 Lee MMY, McMurray JJV, Lorenzo-Almorós A, Kristensen SL, Sattar N, Jhund PS, Petrie MC. Diabetic cardiomyopathy. Heart 2019;105:337-45. [PMID: 30337334 DOI: 10.1136/heartjnl-2016-310342] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
97 Skrtic S, Cabrera C, Olsson M, Schnecke V, Lind M. Contemporary risk estimates of three HbA1c variables in relation to heart failure following diagnosis of type 2 diabetes. Heart 2017;103:353-8. [PMID: 27647169 DOI: 10.1136/heartjnl-2016-309806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
98 Lambadiari V, Thymis J, Kouretas D, Skaperda Z, Tekos F, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Tsoumani M, Chania C, Katogiannis K, Dimitriadis G, Bamias A, Ikonomidis I. Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes. Antioxidants (Basel) 2021;10:1379. [PMID: 34573011 DOI: 10.3390/antiox10091379] [Reference Citation Analysis]
99 Guo Z, Lu J, Li J, Wang P, Li Z, Zhong Y, Guo K, Wang J, Ye J, Liu P. JMJD3 inhibition protects against isoproterenol-induced cardiac hypertrophy by suppressing β-MHC expression. Mol Cell Endocrinol 2018;477:1-14. [PMID: 29753027 DOI: 10.1016/j.mce.2018.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
100 Gulsin GS, Athithan L, McCann GP. Diabetic cardiomyopathy: prevalence, determinants and potential treatments. Ther Adv Endocrinol Metab 2019;10:2042018819834869. [PMID: 30944723 DOI: 10.1177/2042018819834869] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
101 Shaher F, Wang S, Qiu H, Hu Y, Zhang Y, Wang W, Al-Ward H, Abdulghani MAM, Baldi S, Zhou S. Effect and Mechanism of Ganoderma lucidum Spores on Alleviation of Diabetic Cardiomyopathy in a Pilot in vivo Study. Diabetes Metab Syndr Obes 2020;13:4809-22. [PMID: 33335409 DOI: 10.2147/DMSO.S281527] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
102 Castelvecchio S, Menicanti L, Baryshnikova E, de Vincentiis C, Frigiola A, Ranucci M; Surgical and Clinical Outcome Research (SCORE) Group. Comparison of morbidity and mortality in diabetics versus nondiabetics having isolated coronary bypass versus coronary bypass plus valve operations versus isolated valve operations. Am J Cardiol 2011;107:535-9. [PMID: 21185005 DOI: 10.1016/j.amjcard.2010.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
103 Preiss D, van Veldhuisen DJ, Sattar N, Krum H, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Zannad F. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2012;14:909-915. [PMID: 22611047 DOI: 10.1093/eurjhf/hfs067] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
104 Parissis JT, Rafouli-stergiou P, Mebazaa A, Ikonomidis I, Bistola V, Nikolaou M, Meas T, Delgado J, Vilas-boas F, Paraskevaidis I, Anastasiou-nana M, Follath F. Acute heart failure in patients with diabetes mellitus: Clinical characteristics and predictors of in-hospital mortality. International Journal of Cardiology 2012;157:108-13. [DOI: 10.1016/j.ijcard.2011.11.098] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
105 Preiss D, Zetterstrand S, McMurray JJ, Ostergren J, Michelson EL, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, Gerstein HC, Sattar N; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Investigators. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care 2009;32:915-20. [PMID: 19196892 DOI: 10.2337/dc08-1709] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
106 Fritschi C, Redeker NS. Contributions of Comorbid Diabetes to Sleep Characteristics, Daytime Symptoms, and Physical Function Among Patients With Stable Heart Failure. J Cardiovasc Nurs 2015;30:411-9. [PMID: 25078876 DOI: 10.1097/JCN.0000000000000183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
107 Subauste AR, Esfandiari NH, Qu Y, Oral EA, Aaronson KD, Pagani FD, Gianchandani RG. Impact of left ventricular assist device on diabetes management: an evaluation through case analysis and clinical impact. Hosp Pract (1995) 2014;42:116-22. [PMID: 25255413 DOI: 10.3810/hp.2014.08.1124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
108 Standl E, Schnell O, Mcguire DK. Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. Circ Res 2016;118:1830-43. [DOI: 10.1161/circresaha.116.306924] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
109 Saotome M, Ikoma T, Hasan P, Maekawa Y. Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics. Int J Mol Sci 2019;20:E3552. [PMID: 31330848 DOI: 10.3390/ijms20143552] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
110 . Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Revista Española de Cardiología 2008;61:1329.e1-1329.e70. [DOI: 10.1016/s0300-8932(08)75740-3] [Cited by in Crossref: 17] [Article Influence: 1.2] [Reference Citation Analysis]
111 Garbi M, McDonagh T, Cosyns B, Bucciarelli-Ducci C, Edvardsen T, Kitsiou A, Nieman K, Lancellotti P; EACVI Imaging Task Force. Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature review. Eur Heart J Cardiovasc Imaging 2015;16:147-53. [PMID: 25550363 DOI: 10.1093/ehjci/jeu299] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
112 Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG; Authors/Task Force Members., ESC Committee for Practice Guidelines (CPG)., Document Reviewers. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-87. [PMID: 23996285 DOI: 10.1093/eurheartj/eht108] [Cited by in Crossref: 1266] [Cited by in F6Publishing: 1065] [Article Influence: 140.7] [Reference Citation Analysis]
113 Romero SP, Garcia-Egido A, Escobar MA, Andrey JL, Corzo R, Perez V, Garcia-Domiguez GJ, Gomez F. Impact of new-onset diabetes mellitus and glycemic control on the prognosis of heart failure patients: a propensity-matched study in the community. Int J Cardiol. 2013;167:1206-1216. [PMID: 22560913 DOI: 10.1016/j.ijcard.2012.03.134] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
114 Lu KJ, Kearney LG, Ord M, Jones E, Burrell LM, Srivastava PM. Age adjusted Charlson Co-morbidity Index is an independent predictor of mortality over long-term follow-up in infective endocarditis. Int J Cardiol 2013;168:5243-8. [PMID: 23978361 DOI: 10.1016/j.ijcard.2013.08.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
115 Mamas MA, Deaton C, Rutter MK, Yuille M, Williams SG, Ray SG, New J, Gibson JM, Neyses L. Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Card Fail 2010;16:761-8. [PMID: 20797600 DOI: 10.1016/j.cardfail.2010.05.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
116 Macdonald MR, Jhund PS, Petrie MC, Lewsey JD, Hawkins NM, Bhagra S, Munoz N, Varyani F, Redpath A, Chalmers J, Macintyre K, Mcmurray JJ. Discordant Short- and Long-Term Outcomes Associated With Diabetes in Patients With Heart Failure: Importance of Age and Sex: A Population Study of 5.1 Million People in Scotland. Circ Heart Fail 2008;1:234-41. [DOI: 10.1161/circheartfailure.108.794008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
117 Rokicka D, Bożek A, Wróbel M, Nowowiejska-Wiewióra A, Szymborska-Kajanek A, Stołtny T, Gąsior M, Strojek K. Identification of Silent Myocardial Ischemia in Patients with Long-Term Type 1 and Type 2 Diabetes. Int J Environ Res Public Health 2022;19:1420. [PMID: 35162450 DOI: 10.3390/ijerph19031420] [Reference Citation Analysis]
118 Hage FG, Iskandrian AE. Cardiac autonomic denervation in diabetes mellitus. Circ Cardiovasc Imaging 2011;4:79-81. [PMID: 21406659 DOI: 10.1161/CIRCIMAGING.111.963967] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
119 Abdul-rahim AH, Macisaac RL, Jhund PS, Petrie MC, Lees KR, Mcmurray JJ. Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. International Journal of Cardiology 2016;209:310-6. [DOI: 10.1016/j.ijcard.2016.02.074] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
120 Hamnvik OR, Mcmahon GT. Balancing Risk and Benefit with Oral Hypoglycemic Drugs: BALANCING RISK AND BENEFIT WITH ORAL HYPOGLYCEMIC DRUGS. Mt Sinai J Med 2009;76:234-43. [DOI: 10.1002/msj.20116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
121 Guan XH, Hong X, Zhao N, Liu XH, Xiao YF, Chen TT, Deng LB, Wang XL, Wang JB, Ji GJ, Fu M, Deng KY, Xin HB. CD38 promotes angiotensin II-induced cardiac hypertrophy. J Cell Mol Med 2017;21:1492-502. [PMID: 28296029 DOI: 10.1111/jcmm.13076] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
122 Vrtovec B, Sever M, Jensterle M, Poglajen G, Janez A, Kravos N, Zemljic G, Cukjati M, Cernelc P, Haddad F, Wu JC, Jorde UP. Efficacy of CD34+ Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Is Absent in Patients With Diabetes but Preserved in Patients With Insulin Resistance. Stem Cells Transl Med. 2016;5:632-638. [PMID: 27025690 DOI: 10.5966/sctm.2015-0172] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
123 Ehl NF, Kühne M, Brinkert M, Müller-brand J, Zellweger MJ. Diabetes reduces left ventricular ejection fraction-irrespective of presence and extent of coronary artery disease. European Journal of Endocrinology 2011;165:945-51. [DOI: 10.1530/eje-11-0687] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
124 Luan FL, Samaniego M. Transplantation in diabetic kidney failure patients: modalities, outcomes, and clinical management. Semin Dial. 2010;23:198-205. [PMID: 20374550 DOI: 10.1111/j.1525-139X.2010.00708.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
125 MacDonald MR, She L, Doenst T, Binkley PF, Rouleau JL, Tan RS, Lee KL, Miller AB, Sopko G, Szalewska D, Waclawiw MA, Dabrowski R, Castelvecchio S, Adlbrecht C, Michler RE, Oh JK, Velazquez EJ, Petrie MC. Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. Eur J Heart Fail 2015;17:725-34. [PMID: 26011509 DOI: 10.1002/ejhf.288] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
126 Khan MA, Deaton C, Rutter MK, Neyses L, Mamas MA. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev 2013;18:141-8. [DOI: 10.1007/s10741-012-9318-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
127 Zhang B, Su Y, Zhou J, Zheng Y, Zhu D. Toward a Better Regeneration through Implant-Mediated Immunomodulation: Harnessing the Immune Responses. Adv Sci (Weinh) 2021;8:e2100446. [PMID: 34117732 DOI: 10.1002/advs.202100446] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
128 O'meara E, Thibodeau-jarry N, Ducharme A, Rouleau JL. The Epidemic of Heart Failure: A Lucid Approach to Stemming the Rising Tide. Canadian Journal of Cardiology 2014;30:S442-54. [DOI: 10.1016/j.cjca.2014.09.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
129 Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Cohn JN, Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS, Kjekshus J, Køber L, Lepore V, Lucisano G, Maggioni AP, Masson S, Mcmurray JJ, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L, Teli R, Tognoni G, Wikstrand J, Latini R. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes: Insulin treatment and prognosis in chronic HF. Eur J Heart Fail 2018;20:888-95. [DOI: 10.1002/ejhf.1146] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 12.5] [Reference Citation Analysis]
130 Basile G, Crucitti A, Cucinotta MD, Figliomeni P, Lacquaniti A, Catalano A, Morabito N, Buemi M, Lasco A. Impact of diabetes on cognitive impairment and disability in elderly hospitalized patients with heart failure. Geriatr Gerontol Int 2013;13:1035-42. [PMID: 23506006 DOI: 10.1111/ggi.12051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
131 Echeverría LE, Rojas LZ, López LA, Rueda-Ochoa OL, Gómez-Ochoa SA, Morillo CA. Myocardial Involvement in Chagas Disease and Insulin Resistance: A Non-Metabolic Model of Cardiomyopathy. Glob Heart 2020;15:36. [PMID: 32489809 DOI: 10.5334/gh.793] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
132 Marsico F, Gargiulo P, Marra AM, Parente A, Paolillo S. Glucose Metabolism Abnormalities in Heart Failure Patients. Heart Failure Clinics 2019;15:333-40. [DOI: 10.1016/j.hfc.2019.02.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]